IMV INC (IMV) Stock Fundamental Analysis
NASDAQ:IMV - Nasdaq - CA44974L3011 - Common Stock - Currency: USD
Taking everything into account, IMV scores 2 out of 10 in our fundamental rating. IMV was compared to 571 industry peers in the Biotechnology industry. IMV may be in some trouble as it scores bad on both profitability and health. IMV is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IMV has reported negative net income.
IMV had a negative operating cash flow in the past year.
IMV had negative earnings in each of the past 5 years.
In the past 5 years IMV always reported negative operating cash flow.
1.2 Ratios
IMV has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IMV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMV has more shares outstanding
The debt/assets ratio for IMV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -12.68, we must say that IMV is in the distress zone and has some risk of bankruptcy.
IMV has a worse Altman-Z score (-12.68) than 82.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.68 |
ROIC/WACCN/A
WACC6.97%
2.3 Liquidity
IMV has a Current Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.93, IMV is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
IMV has a Quick Ratio of 2.93. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.93, IMV is not doing good in the industry: 70.46% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
IMV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.44%.
Looking at the last year, IMV shows a very strong growth in Revenue. The Revenue has grown by 37.21%.
Measured over the past years, IMV shows a quite strong growth in Revenue. The Revenue has been growing by 14.12% on average per year.
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%
3.2 Future
The Earnings Per Share is expected to grow by 15.36% on average over the next years. This is quite good.
IMV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 162.00% yearly.
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMV's earnings are expected to grow with 17.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.41%
EPS Next 3Y17.34%
5. Dividend
5.1 Amount
No dividends for IMV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.8225
-0.02 (-2.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change-97.69%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.63M
Analysts80
Price Target21.8 (2550.46%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.77%
Min EPS beat(2)18.66%
Max EPS beat(2)24.89%
EPS beat(4)4
Avg EPS beat(4)17.9%
Min EPS beat(4)11.99%
Max EPS beat(4)24.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)362.62%
Min Revenue beat(2)302.87%
Max Revenue beat(2)422.36%
Revenue beat(4)3
Avg Revenue beat(4)202.15%
Min Revenue beat(4)-14.65%
Max Revenue beat(4)422.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.67%
PT rev (3m)-7.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.5%
EPS NY rev (1m)-12.6%
EPS NY rev (3m)-782.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)-84.75%
Revenue NY rev (3m)-88.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 27.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.59
EYN/A
EPS(NY)-3.66
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS0.03
BVpS-0.56
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 107.19% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | -12.68 |
F-Score2
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)151.06%
Cap/Depr(5y)243.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
EPS Next Y20.34%
EPS Next 2Y22.41%
EPS Next 3Y17.34%
EPS Next 5Y15.36%
Revenue 1Y (TTM)37.21%
Revenue growth 3Y-8.54%
Revenue growth 5Y14.12%
Sales Q2Q%337.14%
Revenue Next Year-80.66%
Revenue Next 2Y59.28%
Revenue Next 3Y71.75%
Revenue Next 5Y162%
EBIT growth 1Y-8.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.84%
EBIT Next 3Y-3.45%
EBIT Next 5Y16.26%
FCF growth 1Y-3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.22%
OCF growth 3YN/A
OCF growth 5YN/A